Non-randomized prospective study to verify the usefulness and safety of olanzapine as an antiemetic in transcatheter arterial chemoembolization for hepatocellular carcinoma.

Non-randomized prospective study to verify the usefulness and safety of olanzapine as an antiemetic in transcatheter arterial chemoembolization for hepatocellular carcinoma. - Non-randomized prospective study to verify the usefulness and safety of olanzapine as an antiemetic in transcatheter arterial chemoembolization for hepatocellular carcinoma.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000043188

Enrollment

Registered

2021-04-01

Start date

2021-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

1. At the time of initial treatment 1) Dosing antiemetics (5-HT3 receptor antagonists, NK1 receptor antagonists, steroids) using conventional regimens. Intravenous infusion of paloxenone 0.75 mg bef

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hepatocellular carcinoma with a tumor diameter of 30 mm or more, or more than 2-3 who are recommended for transcatheter arterial chemoembolization as a treatment algorithm for hepatocellular carcinoma.

Exclusion criteria

Exclusion criteria: Those who fall under any of the following are excluded. 1) Patients who received other treatments up to 2 weeks before treatment with transcatheter arterial chemoembolization 2) Patients who have added other treatments such as surgery and radiofrequency ablation immediately after transcatheter arterial chemoembolization 3) Patients with marked decrease in hepatic reserve in Child Pugh classification C 4) Patients with symptomatological brain metastasis / cancerous meningitis 5) Patients who regularly use other antiemetics and antipsychotics 6) Patients with contraindicated items for olanzapine administration (mass ascites, intestinal obstruction, diabetes) 7) Other patients that the research doctor deems inappropriate

Design outcomes

Primary

Measure	Time frame
Achievement rate of complete response (CR) in the late stage (24 to 120 hours after treatment)	—

Countries

Japan

Contacts

Public ContactKyoko Oura

Kagawa University Faculty of Medicine/Graduate School of Medicine Department of Gastroenterology and Neurology

kyoko_oura@med.kagawa-u.ac.jp087-891-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026